baber/WOPTO huggingface dataset:
Patent NZ-525237-A (NZ)
Title: Fire door and method of assembly
Inventor: MOYES HARTLEY
IPC: B29K105/16
Filed: 2001-10-12
Abstract: A fire door (300), comprising: a) a generally rectangular core (301) formed of resin bonded exfoliated vermiculite having a predetermined density; and b) a pair of stiles (302) secured to and extending along opposed edges of the core (301) and a pair of rails (303) secured to and extending along opposed edges of the core (301), the stiles (302) and the rails (303) formed of resin bonded exfoliated vermiculite having a density exceeding the density of the core (301).
Patent NZ-526541-A (NZ)
Title: Inkjet recording apparatus and ink cartridge
Inventor: HARADA KAZUMASA
IPC: B41J2/175
Filed: 2003-06-17
Abstract: Disclosed is an ink cartridge capable of being removably held in an ink cartridge accommodation portion simply by pushing in the cartridge in an insertion direction. The ink cartridge (5) is mounted in a carriage (4) having a cartridge accommodation region. A one-push type fixing member (30) in a position facing a surface parallel to an insertion direction in which the cartridge is inserted into the cartridge accommodation region is engaged with a fixing protrusion (12a) forming another one-push type fixing member, so that the cartridge is held in s predetermined position in a state in which the cartridge is resiliently urged by a spring (24) in a direction opposite to the insertion direction.
Patent NZ-527209-A (NZ)
Title: Neurotrophic tacrolimus analogs
Inventor: MATSUOKA NOBUYA
IPC: A61P25/28
Filed: 2001-12-31
Abstract: Disclosed is the used of compounds of formula (I) for the manufacture of a neurotrophic agent, such as for preventing or treating neuronal injury/dysfunction, promoting nerve cell growth or regeneration, or for promoting functional recovery from a nerve injury.
Patent NZ-527338-A (NZ)
Title: Anti-interferon-alpha antibodies
Inventor: KIM JIN K
IPC: A61P3/10
Filed: 2002-01-29
Abstract: An anti-IFN-alpha monoclonal antibody which binds to and neutralizes a biological activity of at least IFN-alpha subtypes IFN-alpha1, IFN-alpha2, IFN-alpha4, IFN-alpha5, IFN-alpha8, IFN-alpha10, and IFN-alpha21. Preferably the anti-IFN-alpha antibody comprises a light chain with CDRs: L1 of the formula RASQSVSTSSYSYSYMH, L2 of the formula YASNLES, and L3 of the formula QHSWGIPRTF; and/or a heavy chain or fragment with CDRs: H1 of the formula GYTFTEYIIH, H2 of the formula SINPDYDITNYNQRFKG and H3 of the formula WISDFFDY. Also described are vectors, isolated host cells, hybridoma cell lines, method of diagnosing a condition associated with the expression of IFN-alpha and the use of the anti-IFN-alpha antibody to treat a disease or condition associated with the expression of IFN-alpha in a patient, for example insulin-dependent diabetes mellitus (IDDM), systemic lupus erythematosus (SLE); and autoimmune thyroiditis.
Patent NZ-529529-A (NZ)
Title: An active message delivery service
Inventor: MAGNELL STEVEN
IPC: H04L12/00
Filed: 2003-11-17
Abstract: A system for active message delivery comprises: at least one session control device (271) that is capable of requesting and controlling a communications session with a terminal via at least one real-time communications network (100); at least one media device (272) capable of transmitting media to a terminal via at least one real-time communications network; at least one media device (272) capable of receiving media from a terminal via at least one real-time communications network; at least one media device (272) capable of transmitting store and forward media to a terminal; at least one media device (272) capable of receiving store and forward media from a terminal; a message candidate store (210) for holding records that contain parameters for a communications transaction to be executed with at least one user located at least one terminal; at least one media analysis engine (260) capable of extracting user responses from media data received from a terminal; at least one media transform engine (250) capable of converting media from a source form to one that can be transmitted to, and accepted by, a terminal; a message result store (240) for holding records that contain intermediate and final result data generated by the execution of contact scripts and message scripts; a message script store (215) containing message scripts that prescribe the rules by which the message content of at least one media type is assembled and delivered; the rules by which responses from the target user is solicited, extracted from received media data and recorded in the message result store; the rules by which progress and status information is stored in the message result store; the rules by which information stored in the result store is retrieved and used to modify the way in which subsequent content is delivered; the rules by which a user at a terminal is authenticated as being the desired target; a message script interpreter (230) that executes the steps specified in the message scripts contained in the message script store; a means of communications by which at least one client application submits at least one message delivery transaction for execution by the active message delivery system, monitors progress of said transactions and receives termination results from completed message delivery transactions; a means of binding asynchronous responses from terminals to the message delivery transaction to which they apply; a contact script interpreter (220) configured to determine the sequence and timing of contact attempts and the address to be used for each contact attempt by application of rules defined in the contact scripts held within the message candidate store.
Patent NZ-530723-A (NZ)
Title: New assays for PFI using the anti-CD2 antibodies T11 and preimplantation factor peptides
Inventor: BARNEA EYTAN
IPC: C07K7/06
Filed: 2002-06-28
Abstract: A method for determining the presence of preimplantation factor in a sample comprises determining whether the sample contains a component which inhibits the binding of an anti-CD2 antibody to CD2 antigen, wherein the ability to inhibit the binding has a positive correlation with the presence of preimplantation factor. Also described are PIF peptides having the sequence Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala, Val-Ile-Ile-Ile-Ala-Gln-Tyr-Met-Asp, Ser-Gln-Ala-Val-Gln-Glu-His-Ala-Ser-Thr, Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala-Asn-Lys-Pro-Ser, Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala-Asn-Lys-Pro-Ser-Asp, Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala-Asn-Lys-Pro-Ser-Asp-Asp, or Ser-Glu-Ilie-Val-Ile-Tyr-Gln-Tyr-Met-Asp-Asp-Arg-Tyr-Val-Gly-Ser-Asp-Leu.
Patent NZ-533657-A (NZ)
Title: Methods for the preparation of immunoconjugates, in particular maytansinoids conjugated to a monoclonal antibody
Inventor: MAZZOLA GREGORY L
IPC: A61K47/48
Filed: 2003-01-02
Abstract: Disclosed is a method for conjugating a maytansinoid to an antibody comprising; reacting a disulfide-containing linker with the antibody to form a modified antibody; removing unreacted linker from the modified antibody by tangential flow filtration; conjugating the modified antibody with the maytansinoid in a solvent comprising dimethylacetamide; and purifying the antibody via ion exchange chromatography.
Patent NZ-535852-A (NZ)
Title: Cement paint
Inventor: TERRUZZI CLAUDIO
IPC: C09D1/08
Filed: 2004-10-11
Abstract: A cement paint is disclosed which comprises a pigmenting substance, a cement binder and a fluidizing liquid, and further comprising at least: a calcareous aggregate comprising calcareous granules of calcium carbonate having maximum sizes smaller than 100 microns, a vitreous aggregate comprising vitreous granules having maximum sizes smaller than 100 microns,and a photo catalyst to oxidize polluting substances in the presence of light and air, wherein said calcareous granules and vitreous granules have sizes similar to each other. The presence of vitreous granules and calcareous granules with similar sizes increases the hardness and the brightness of the cement paint.
Patent NZ-536424-A (NZ)
Title: Interactive system
Inventor: MOCKETT RICHARD JOHN
IPC: G06F19/00
Filed: 2004-11-08
Abstract: The invention relates to a digital system for providing services to a patient in a health care environment, such as a hospital, comprising a means to display data, means operable by a user to select desired data and activate the display means, and remote data store means such as servers adapted to provide data digitally to the display means when accessed by the user. The overall system can provide patient access to entertainment, communication, and medical data relating to that patient and held by or on a hospital data base. The medical condition of each patient, in other words an inventory of medical data, is thus accessible.
Patent NZ-537608-A (NZ)
Title: Novel 2-pyridylethylbenzamide derivative
Inventor: COOKE TRACEY
IPC: C07D213/61
Filed: 2003-08-08
Abstract: Described is a compound of the general formula (I), wherein: p is an integer 1,2,3 or 4; q is an integer 1, 2, 3, 4 or 5; each substituent X is chosen, independently of the others, as being halogen, alkyl or haloalkyl, at least one of the substituents being a haloalkyl; each substituent Y is chosen, independently of the others, as being halogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, amino, phenoxy, alkylthio, dialkylamino, acyl, cyano, ester, hydroxy, aminoalkyl, benzyl, haloalkoxy, halosulphonyl, halothioalkyl, alkoxyalkenyl, alkylsulphonamide, nitro, alkylsulphonyl, phenylsulphonyl or benzylsulphonyl. An exception is N-{2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl}-2,6-dichlorobenzamide. The process for the preparation of a compound of formula (I) is disclosed. A method for preventively or curatively combating the phytopathogenic fungi of crops is also described. The method is characterised in that an effective and non-phytotoxic amount of a composition described herein is applied to the plants or seeds or to the soil in which the plants are growing in.
Patent NZ-537998-A (NZ)
Title: Isolated mutant serum albumin which has been mutated such that it displays an altered metal binding affinity and/or physiological other characteristic(s) with respect to a native albumin
Inventor: BEREZENKO STEPHEN
IPC: C12N5/071
Filed: 2003-07-28
Abstract: An isolated mutant human serum albumin comprising the amino acid sequence: DAHKSEVAHRFKDLGEENFKALVLIAFAQX5LQQCPFEDHV KLVNEVTEFAKTCVADESAENCDKSLX1TLFGDKLCTVATL RETYGEMADCCAKQEPERX2X8CFX6QHKDDNPNLPRLVRPE VDVMCTAFHDNEETFLKKYLYEIARRX9PYFYAPELLFFAKR YKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTK VX10TECCX3X7X4LLECADDRADLAKYICENQDSISSKLKEC CEKPLLEKSX11CIAEVENDEMPADLPSLAADFVESKDVCKN YAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLE KCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLG EYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCK HPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTES LVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQ IKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKAD DKETCFAEEGKKLVAASQAALGL wherein X1, is other than H; X2 is other than N, X3 is other than H, X4 is other than D; X5 is other than Y; X6 is other than L; X7 is other than G, X8 is other than E, X9 is other than H, X10 is other than H, and/or X11 is other than H, such that said mutant displays an altered metal binding affinity with respect to native human serum albumin.
Patent NZ-538667-A (NZ)
Title: A down-pipe connector
Inventor: LUCAS CHRISTOPHER FRANCIS
Filed: 2005-04-14
Abstract: A connector having an inlet and an outlet and an additional by-pass outlet portion. The by-pass portion is moveable between two configurations; a non by-pass configuration and a by-pass configuration, wherein when the by-pass portion is in the non by-pass configuration this allows liquid to pass through the inlet and exit the outlet; and when the by-pass portion is in the by-pass configuration there is a region of the internal surface of the connector which at least partially overlaps the by-pass portion so that liquid entering the inlet can be redirected along the by-pass portion and out the by pass outlet to effectively prevent liquid from exiting the outlet.
Patent NZ-541057-A (NZ)
Title: Mixing dispenser
Inventor: PEARCE ALISDAIR GILBERT
IPC: A61J1/03
Filed: 2003-12-24
Abstract: A dispenser (1) comprises a container having a first aperture (not shown) therein and a first closure means (not shown) for sealingly closing the first aperture and is characterised in that the container has a second aperture (3) and a second closure means (4) for closing said second aperture, said second closure means including a pressing means (5) operable to press inwardly towards said second aperture (3), a blister pack (6), locating means (8, 9) locating said blister pack to span across said second aperture (3) and sealing means (7, 10) sufficient to ensure the second aperture is sealingly closable against leakage of the intended contents of the dispenser. The construction and arrangement is such that in end use the container holds a first substance and the blister pack holds a second substance and when the pressing means is pushed the blister pack is ruptured enabling the mixing of the contents thereof with those of the container.
Patent NZ-542412-A (NZ)
Title: Method for heating a gondola of a cableway system
Inventor: HINTEREGGER CHRISTOPH
Filed: 2005-09-15
Abstract: A method for heating a gondola (1) of a cableway system is disclosed, whereby at least one part of the base (6) of the gondola (1) is heated by an electrical heating device. The duration and/or intensity of the power supply is regulated in a manner dependent on the local external temperature, and the power supply of the heating device is interrupted as soon as the temperature of the heated part of the base (6) has reached a predetermined maximum temperature.
Patent NZ-542577-A (NZ)
Title: Animal model for the fast identification of pharmaceutical active compounds in vivo
Inventor: BELIEN ANN TRUDO JOSEE
IPC: C12Q1/68
Filed: 2004-03-03
Abstract: Disclosed is a stably transformed tumor cell which has been transfected with an expression vector comprising a reporter gene operably linked to a promoter that also controls expression of a protein that is associated with tumor regression, stabilisation of tumor growth or inhibition of metastatic growth, and wherein the promoter consists of a P21WAF-1/CIP-1 1300 bp promoter fragment wherein said promoter fragment does not comprise the p53 responsive elements. Also disclosed are methods of screening for compounds having anti-neoplastic active and non-human animal models comprising the stably transfected tumor cell for use in said methods.
Patent NZ-543927-A (NZ)
Title: Method of forming barbs on a suture and apparatus for performing same
Inventor: GENOVA PERRY A
IPC: A61B17/064
Filed: 2002-08-29
Abstract: A method of cutting barbs on a suture having a longitudinal axis, the method comprising the steps of: providing a suture having x-y-z axes; providing a cutting blade; creating a barb on the suture by the motion of the blade which takes into account a cutting action by the blade on the suture in three dimensions along the x-y-z axes of the suture caused by blade geometry in conjunction with blade motion, with the blade having motion at least along the x-axis; and providing a means for moving the blade to cause said cutting action to create the barb. A twist-cut spiral barbed suture made by the method is also provided.
Patent NZ-553898-A (NZ)
Title: Device for needleless injection operating with two concentric energetic materials
Inventor: ALEXANDRE PATRICK
IPC: A61M5/30
Filed: 2005-09-20
Abstract: The disclosure concerns pre-filled and disposable needleless injection devices, operating with a gas generator, and used for intradermal, subcutaneous and intramuscular injections. The invention concerns a needleless injection device (1) comprising a pyrotechnical gas generator (2), at least one plunger (13, 14), a liquid active principle reservoir (8) and an injection nozzle (11). The device is mainly characterized in that said generator (2) comprises a pyrotechnical charge (4) consisting of a central energetic material surrounded by a second peripheral energetic material, the two energetic materials having different combustion speeds.
Patent NZ-556747-A (NZ)
Title: Template-fixed beta-hairpin peptidomimetics with protease inhibitory acitivity
Inventor: DEMARCO STEVEN J
IPC: C07K7/08
Filed: 2005-02-17
Abstract: Disclosed are compounds of the general formula (I) which have selective protease inhibitory activity (in particular against Cathepsin G or Elastase or Tryptase), wherein the group ûC(=O)-[Template]-N- is a group of one of the formulae (a1) or (a2), and Z is a chain of 11 ß-amino acid residues, the other substituents are defined herein. Also disclosed is a pharmaceutical composition containing one of the above compounds and a pharmaceutically inert carrier in a form suitable for oral, topical, transdermal, buccal, transmucosal or pulmonary administration or for administration by injection or inhalation. In addition, the use of the above compounds for the manufacture of a medicament for use as an inhibitor of protease enzymes is also disclosed (wherein the use of the said protease inhibiting medicament is intended to be used for preventing infections in healthy individuals, or for slowing infections in infected patients; or where cancer is mediated or resulting from; or where an immunological disease is mediated or resulting from protease activity or where inflammation is mediated or resulting from protease activity; or where an immunological reaction is mediated by or resulting from protease activity).
Patent NZ-562481-A (NZ)
Title: Method of land management involving microbial bioassay
Inventor: HAFEEL KALIDEEN
IPC: C12Q1/04
Filed: 2006-03-16
Abstract: Provided is a method for measuring soil quality of a soil sample by a microbial bioassay by at determining fungal-bacterial ratio by substrate induced respiration combined with selective inhibition by multiple soluble inhibitors in solution, the fungal-bacterial ratio data having an inhibitor additivity ratio (lAR) of 1.00 (± 0.15), where IAR = (A-B)+(A-C) / (A-D) and A is total soil biomass, (A-B) is the difference between total soil biomass and biomass in the presence of fungal inhibitor(s) (treatment B), (A-C) is the difference between total soil biomass and biomass in the presence of bacterial inhibitors (treatment C); and (A-D) is the difference between the total soil biomass and biomass in the presence of both fungal and bacterial inhibitors (treatment D) at similar concentrations to treatments Band C, wherein said multiple soluble inhibitors are selected with reference to the sampled soil. The method can form the basis of soil remediation and land management strategies.
Patent NZ-562803-A (NZ)
Title: Pesticidal compositions comprising an azole, a phenylamide and a strobilurin and/or phenylpyrrole fungicide
Inventor: ZEUN RONALD
IPC: A01N47/32
Filed: 2006-05-02
Abstract: Disclosed is a pesticidal combination comprising at least three active ingredient components optionally together with one or more customary formulation auxiliaries, wherein component (I) is one or more of an azole fungicide selected from thiabendazole, oxpoconazole, ipconazole and prothioconazole, component (II) is one or more of a phenylamide fungicide, and component (III) is one or more of a phenylpyrrole fungicide. A method of controlling or preventing pathogenic damage or pest damage in a plant propagation material, a plant, parts of a plant and/or plant organs that grow at a later point in time is also disclosed, which comprises applying the said pesticidal combination on the plant, part of the plant, or surroundings thereof.
Patent NZ-575868-A (NZ)
Title: Garnulated compositions and their use
Inventor: VOYCE WARWICK GEORGE
IPC: A23L29/00
Filed: 2009-03-25
Abstract: Disclosed is a dietary supplement granules, each granule being a granulation of consistent mix ratio of at least three types of particle, the particles being (i) particles of a particulate source of calcium not in the zero oxidation state and in a nutritionally available form ("calcium, particles"), (ii) particles of magnesium oxide, and (iii) particles of sodium chloride wherein the calcium particles when expressed as calcium carbonate comprises from 50 to 90 percent w/w of the granules, the magnesium oxide particles comprise at least 5 percent w/w of the granules but is less than the percent w/w of the calcium particles and the sodium chloride particles comprise from 5 to 30 percent w/w of the granules; and wherein the particles of each granule are of varied size within each particle type and/or between particle types and wherein each granule, to the extent it has a moisture content, it is at a moisture content less than that at which granulation has occurred.
Patent NZ-576119-A (NZ)
Title: Combination therapy involving egf inhibitors
Inventor: JOHNSTON JAMES
IPC: C07K16/22
Filed: 2007-10-11
Abstract: Provided is the use of an inhibitor of HB-EGF and an inhibitor of AREG in the preparation of a medicament formulated for simultaneous or sequential use in the combination treatment of neoplastic disease; wherein, in said combination treatment, said inhibitor of HBEGF and said inhibitor of AREG act synergistically; wherein said inhibitor of HB-EGF is an antibody molecule which binds said HB-EGF or a nucleic acid molecule which inhibits expression of HB-EGF; and wherein said inhibitor of AREG is an antibody molecule which binds AREG or a nucleic acid molecule which inhibits expression of AREG. Further provided are compositions comprising the two inhibitors and specific amino acid sequences of the antibodies therein.
Patent NZ-586975-A (NZ)
Title: Canine influenza vaccine comprising a expression vector which expresses a polynucleotide encoding a equine influenza antigen
Inventor: MINKE JULES MAARTEN
IPC: A61K39/145
Filed: 2009-01-27
Abstract: Disclosed is a method for providing a Canidae with protective immunity against canine influenza comprising administering to said Canidae an effective amount of a vaccine comprising an effective amount of a canarypox expression vector that contains and expresses in vivo in a canine a polynucleotide encoding equine influenza antigen comprising equine influenza H3 operatively linked to a promoter and optionally to an enhancer, and a pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle, thereby providing the protective immunity.
Patent NZ-589704-A (NZ)
Title: Sectional folding door of sheet like elements that lie flat against each other above the door when open
Inventor: LANGENBACH GUIDO
IPC: E06B3/92
Filed: 2009-04-30
Abstract: 589704 A sectional folding door (1) for closing a wall opening (2) is disclosed in which the sections (3) lie flat against each other in an open position. The door comprises at least two sheet-like elements (3) that are retained in at least two guide rails (4) by the rollers (8) of a guiding and separating device (6). Each guiding and separating device (6) is comprised, in the closed position, of a lever with a horizontal arm (7a) and a vertical arm (7b). The vertical arm (7b) is retained in an inner running track (5) via a roller (9). An outer guide rod (13a) attached to an upper sheet-like element and an inner guide rod (13b) attached to a lower sheet like element are connected to the horizontal arm (7a) in an articulated manner. The guide rods (13a, 13b) are displaceable along the horizontal arm (7a) in parallel channel-like recesses in the arm (7a). The guiding and separating device (6) allows the sheet-like panels to be guided from a closed position covering the opening to a closed position stacked flat above the opening (2).
Patent NZ-598648-A (NZ)
Title: Polygonal dice with 3D markings on the edges
Inventor: NAGY RICHARD
IPC: A63F9/04
Filed: 2010-09-03
Abstract: A game accessory, especially dice comprises a polygonal body 1 delimited by side surfaces 2, markings 5 projecting a different overall impression and/or information each, arranged on the body 1 according to a predetermined rule. The markings 5 are created as spatial 3D local mechanical depressions along the joining edges 3 of the side surfaces 2 delimiting the body 1.